- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | Revolution Med shoots for $100M+ IPO - and divulges some secrets about that Warp Drive buyout | ||
| Fr | At JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell | ||
| Fr | Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO | ||
| Fr | Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel | ||
| Fr | China's fourth richest man takes a back seat at the top drugmaker he built | ||
| Fr | Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication | ||
| Fr | In active shopping mode, Eli Lilly plots one deal per quarter as it scouts 'Dermira-like' assets up to $5B | ||
| Fr | First Chinese biotech on Nasdaq in two years draws $104M | ||
| Fr | Germany's IQWiG finds first tumor-agnostic drug provides no added benefit | ||
| Fr | Hung jury vote leaves FDA with a difficult decision on Durect's non-opioid painkiller | ||
| Fr | BioMarin execs discuss some eye-popping numbers for the price of valrox - but haven't we heard this before? | ||
| Do | JPM20: Five years after first PCSK9, Novartis goes for win as Sanofi moves on, Amgen salvages what's left | ||
| Do | Mayo Clinic launches clinical analytics platform with nference; WuXi buys German plant from Bayer | ||
| Do | The FDA: Faster, but not necessarily stronger - analysis finds | ||
| Do | JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of a mammoth fund debut | ||
| Do | Frazier closes 10th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more | ||
| Do | Neon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal | ||
| Do | Biopharma's China plan gets a boost from patent protections sealed in now official trade deal | ||
| Do | Government spending bill tweak means 3 more NDAs will become BLAs, FDA says | ||
| Do | GSK, Pfizer contradict on the future of consumer health JV - report | ||
| Do | JPM20: After Year of NASH collapses, all eyes on two biotechs | ||
| Mi | Video Replay: Endpoints at JPM20 - newsmakers on dealmaking, pricing and manufacturing | ||
| Mi | Celgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available | ||
| Mi | FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing | ||
| Mi | FDA staff offer few clues on their stance on Durect's pain drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
